Artificial Intelligence

DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431

Published

3 years ago

March 23, 2021

EDISON, N.J., March 23, 2021 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) – driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced positive results from an in vivo study of CRV431 in a Diet-Induced Animal Model Of Non-alcoholic fatty liver Disease (“DIAMOND”).¹

It is estimated by the National Institutes of Health, that between 3% – 12% of the U.S. adult population has NASH.² There are currently at least 90 drug candidates targeting NASH in various stages of development.³ The majority of these drug candidates are designed to target metabolic perturbations leading to the pathogenesis of NASH and thereby seek to normalize glycemic control, lipid metabolism, and insulin resistance, to name a few. Few drug candidates directly target fibrosis, either through fibrogenesis and/or fibrolysis, despite fibrosis being a major prognostic indicator of liver-related and overall mortality.⁴ Hepion’s clinical drug candidate, CRV431 administered once daily orally, seeks to target fibrosis, and the company’s latest in vivo animal study further lends validity to this mechanism.

“Nonclinical animal efficacy models have been designed to recapitulate human disease. However, questions remain regarding the validity of these models and whether they are truly predictive of clinical efficacy outcomes,” commented Dr. Daren Ure, Hepion’s Chief Scientific Officer. “This uncertainty can be partly alleviated by performing nonclinical studies in many different types of experimental models to test the robustness of a drug’s effects. For this reason, we have conducted 9 individual animal studies of fibrosis and found consistent and statistically significant antifibrotic effects of CRV431 in every one of these studies. Antifibrotic activity has also been observed in previously reported studies conducted by an independent U.K. laboratory that studied explanted liver and lung tissues taken from human donors. Taken together, these animal and human tissue experiments give us a great deal of confidence that CRV431 has beneficial antifibrotic effects that are expected to be borne out clinically.”

“The results obtained with the DIAMOND mouse experiment confirm, once again, that CRV431 is a potent antifibrotic agent,” commented Dr. Philippe Gallay, Professor of Immunology, at the Scripps Research Institute in San Diego. “This model of NASH was originally developed by Dr. Arun Sanyal, a global leader in the development and treatment of therapies for NASH. In this study, our laboratory established NASH by feeding animals with a fat- and sugar-enriched Western diet for 34 weeks, followed by 8 weeks treatment with oral dosing of CRV431 or two comparator drugs, obeticholic acid and elafibranor. Fibrosis was reduced, as determined using Picrosirius Red staining, by 47% with CRV431, 35% with obeticholic acid, and 37% with elafibranor, relative to vehicle controls. A 47% reduction in fibrosis with CRV431 is an incredible result, and this highlights that a relatively short course of CRV431 treatment can exert beneficial effects at an advanced stage of liver disease in a model having many similarities to human NASH.”

A summary of CRV431’s nonclinical in vivo antifibrotic activity is shown in the following table:

Model	Oral Dose (animal)	Dosing Duration	Fibrosis Reduction (Organ)	Statistical Significance
DIAMOND	50 mg/kg (mouse)	8 weeks	47% (liver)	Significant p<0.0001
Streptozotocin (“STAM”) plus High Fat Diet (“HFD”)	20 mg/kg (mouse)	3 weeks	57% (liver)	Significant p<0.01
STAM plus HFD	50 mg/kg (mouse)	6 weeks	46% (liver)	Significant p=0.03
STAM plus HFD	50 mg/kg (mouse)	11 weeks	37% (liver)	Significant p=0.01
STAM plus HFD	50 mg/kg (mouse)	10 weeks	44% (liver)	Significant p=0.014
Western Diet + CCl₄	50 mg/kg (mouse)	6 weeks	82% (liver)	Significant p<0.0001
Thioacetamide	40 mg/kg (rat)	9 weeks	48% (liver)	Significant p=0.008
CCl₄	50mg/kg (mouse)	6 weeks	43% (liver)	Significant p=0.005
Unilateral Ureteral Obstruction	50 mg/kg (mouse)	2 weeks	42% (kidney)	Significant p=0.0006

Dr. Patrick Mayo, Hepion’s Senior Vice-President, Clinical Pharmacology and Analytics continued, “As previously reported, we have completed the 75 mg dosing cohort with CRV431 in our ongoing Phase 2a clinical study in NASH subjects, and recruitment is continuing for the 225 mg dosing cohort. While this 28-day trial is focused on the safety and pharmacokinetics of CRV431, the data show that 75 mg CRV431 dosing decreased serum transaminases (ALT, AST) from baseline, consistent with a beneficial effect on the liver. Histologic changes are not being evaluated in this study due to the short duration of treatment, but additional evidence of therapeutic effects is being sought from an extensive multi-omics program. Thousands of genes, proteins, and lipids from patients are being monitored and analyzed with Hepion’s AI-POWR™ platform to look for potential biomarkers and early signs of CRV431 efficacy that may translate to structural and functional improvements to patient livers over the longer term. Similar multi-omic studies in DIAMOND and other nonclinical models help to strengthen predictions to apply to future clinical studies.”

“Overall, this is all about helping patients and developing a comprehensive risk mitigation strategy in our drug development program,” commented Dr. Robert Foster, Hepion’s Chief Executive Officer. “We know that drug development is expensive, time-consuming, and risky. Broadly speaking, companies like Hepion are faced with two major risk hurdles – drug development risk and financing risk. We recently significantly mitigated our financing risk via a successful public offering, and now we believe we are helping reduce our clinical development risk by employing numerous nonclinical efficacy models, including the recent DIAMOND model, human explanted liver tissues, and our proprietary AI.”

Dr. Foster concluded, “We are relying on the expertise of our highly experienced team to effectively use all available tools to maximize the chances of CRV431’s clinical success. In that regard, we look forward to the top-line read-out of our Phase 2a NASH study in the near future.”

¹ https://doi.org/10.1016/j.jhep.2016.05.005

² Bell, J. No one knows the size of the NASH market. BioPharma Dive. https://www.biopharmadive.com/news/no-one-knows-the-size-of-the-nash-market/554240/ (2019).

³Nonalcoholic Steatohepatitis Drug Pipeline Analysis Review, 2020. DelveInsight Business Research LLP.

⁴Taylor, R.S.; Taylor, R.J.; Bayliss, S., et al. Association Between Fibrosis Stage and Outcomes of Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology, 2020, 158(6):1611-1625.

About Hepion Pharmaceuticals

The Company’s lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease – from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies.

Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence – Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing Phase 2a NASH program, Hepion will use the platform to identify additional potential indications for CRV431 to expand the company’s footprint in the cyclophilin inhibition therapeutic space.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among others. These forward-looking statements are based on Hepion Pharmaceuticals’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; risks associated with delays, increased costs and funding shortages caused by the COVID-19 pandemic; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2019 and other periodic reports filed with the Securities and Exchange Commission.

For further information, please contact:

Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
[email protected]

Related Topics:AI Artificial Intelligence Machine learning

Up Next

CloudMD Announces Closing of IDYA4 Acquisition and North American roll out of Substance Use Disorder Platform to Address Growing Addiction Crisis

Don't Miss

GZ6G Technologies Introduces Green Zebra Data Centers Division

GlobeNewswire

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Asia Mobiliti Applauded by Frost & Sullivan for Powering Intelligent Urban Mobility and Offering Customer Value with Its MaaS Solutions

Published

1 hour ago

June 26, 2024

CISION (PR Newswire)

asia-mobiliti-applauded-by-frost-&-sullivan-for-powering-intelligent-urban-mobility-and-offering-customer-value-with-its-maas-solutions

Asia Mobiliti’s efficient, sustainable, and interconnected mobility solutions improve user experience, reduce congestion and environmental impact, and reshape urban spaces.
SAN ANTONIO, June 26, 2024 /PRNewswire/ — Frost & Sullivan recently researched the mobility-as-a-service (MaaS) industry and, based on its analysis, recognizes Asia Mobiliti with the 2024 Asia-Pacific (APAC) Customer Value Leadership Award. As a pioneering start-up, the company has dedicated itself to reshaping urban mobility by actively developing innovative data products. It specializes in designing, engineering, and operating a cutting-edge data platform aimed at powering intelligent urban mobility. The platform seamlessly connects fleet operators, transport providers, transit authorities, and end users through a data-driven approach. The company’s comprehensive suite of products and services include:

Internet of Things (IoT) and Machine Learning powered digital city solutionsMaaS technologiesDemand-Responsive Transit systemsMobility data servicesAsia Mobiliti’s unique mobility platform integrates IoT and telematics with journey planning, enabling it to lead transport digitalization. The company catalyzes innovative data-driven and artificial intelligence solutions for the transit and mobility ecosystem, facilitating the widespread adoption of MaaS across emerging markets. Asia Mobiliti is at the forefront of revolutionizing intelligent urban mobility, offering diverse products and services. The company’s connected vehicle systems provide real-time tracking and monitoring capabilities for vehicles and fleets. These systems have analytics tools that optimize routes, enhance fuel efficiency, and improve fleet performance. Asia Mobiliti places a significant emphasis on mobility data services, utilizing the power of data to offer valuable insights for informed decision-making processes. Over the long term, it envisions reducing congestion, reducing environmental impact, and reshaping urban spaces while replacing spaces traditionally reserved for parking and traffic with more sustainable, natural living spaces.
Ming Lih Chan, industry principal for Frost & Sullivan’s mobility practice, observed, “Asia Mobiliti disrupts the traditional transportation system model and promotes the development of public travel needs. Its MaaS integrates multiple transportation modes and combines private and public modes of transport with demand-responsive services, which sustainably meets the different needs of the public.”
Asia Mobiliti’s Trek Rides and Trek App solutions represent a paradigm shift in urban mobility. Trek Rides, an on-demand transit service, efficiently fills the first-mile/last-mile gaps by merging the convenience of ride-hailing with the dedicated supply of public transport. This reduces traffic congestion, lowers travel costs, and facilitates the shift towards net-zero emission goals. Trek’s MaaS engine employs advanced algorithms for comprehensive multimodal journey planning, ensuring the seamless integration of various transportation modes. Additionally, Trek API facilitates integration with 3rd-party systems and super apps. Asia Mobiliti’s unique selling proposition lies in its compelling price/performance value within the highly competitive mobility services landscape, granting it a distinctive competitive edge in effectively addressing a broad spectrum of client needs.
“Asia Mobiliti underlines its supremacy in the MaaS sector through its strategic commitment to collaboration and customization. The company is a pivotal partner for governments, transit authorities, and large clients, offering a user-friendly platform backed by cutting-edge technology. Asia Mobiliti earns recognition as the best-in-class provider in the dynamic MaaS landscape for its operational efficiency, consistent revenue growth, and forward-looking expansion strategy,” added Norazah Bachok, best practices research analyst at Frost & Sullivan. As a cost-effective and innovative market player, the company solidifies its position by delivering exceptional client value.
Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in implementing strategies that proactively create value for customers with a focus on improving the return on the investment that customers make in its services or products. The award recognizes the company’s unique focus on augmenting the value that its customers receive, beyond simply good customer service, leading to improved customer retention and customer base expansion.
Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact us: Start the discussion.
Contact:
Tarini SinghP: +91 9953764546E: [email protected]
About Asia MobilitiFounded in 2018 and based in Kuala Lumpur, Malaysia, Asia Mobiliti is an award-winning, Malaysia Digital status company providing a Mobility-as-a-Service (MaaS) platform and digital city solutions designed and engineered for the developing world. We adopt a technology platform approach with a core software-defined engine that is capable of spawning innovative mobility solutions that encompass Internet of Things (IoT)-enabled advanced telematics, machine learning-based mobility-as-a-service technology, as well as a wide variety of transit technologies, such as demand-responsive transit, transport service analytics, condition monitoring for rail and road and account-based ticketing and payments.
For more information, visit asiamobiliti.com or email [email protected]
Photo – https://mma.prnewswire.com/media/2447280/Frost_and_Sullivan_2024_Asia_Mobiliti_Award_.jpg

View original content:https://www.prnewswire.co.uk/news-releases/asia-mobiliti-applauded-by-frost–sullivan-for-powering-intelligent-urban-mobility-and-offering-customer-value-with-its-maas-solutions-302182092.html

Artificial Intelligence

More than 150,000 money laundering accounts detected in APAC

Published

5 hours ago

June 26, 2024

CISION (PR Newswire)

Region sees 108% increase in voice scams as fraudsters continue shift to mobile
MELBOURNE, Australia and MUMBAI, India, June 25, 2024 /PRNewswire/ — A new financial crime report out today details how criminal organizations in the APAC region now outsource the laundering of money stolen via scams to international syndicates specializing in this cleaning. BioCatch identified and helped APAC banks shut down more than 150,000 money mule accounts in 2023 and estimates exponentially more such accounts in use across the region.

“Where there are scams, there are mules,” BioCatch Director of Global Fraud Intelligence Tom Peacock said. “Criminal organizations use these mule accounts as intermediate stops between the victim’s bank account and the final account from which they plan to withdraw their stolen money. The mules we’ve identified almost certainly represent a tiny fraction of those actively laundering money in the region, with more cropping up every day. Financial institutions in APAC and around the world must do more to identify these mules, hamper their ability to open new accounts, and identify those legitimate accounts money launderers succeed in turning from good to bad.”
In this latest edition of its Digital Banking Fraud Trends in APAC report, BioCatch – which identifies and prevents fraud and financial crime in real time by analyzing as many as 3,000 different physical behavior patterns (mouse movements and typing speed, for example) and cognitive signals (hesitation, segmented typing, etc.) in search of anomalies – points to mobile malware as the greatest threat to banks in Southeast Asia in 2024.
“Whether through SMS-mining or illegal loan apps, we’ve seen an explosion in Android-based malware in the region,” Peacock said. “Malware developers continue to innovate, circumventing bank and Google Play Store defenses to harvest what they need from mobile devices to access digital banking accounts and then transfer away the victim’s funds to a money mule.”
There is reason for hope in fighting fraud in APAC, however. In Australia, the number of reported scam cases grew by 13% in 2023, but scam losses declined by $90 million.
“Nine out of the 10 largest Australian banks employ BioCatch solutions to protect their customers from fraud and financial crime by analyzing the behavior of the user behind every online banking session,” BioCatch APAC Vice President Richard Booth said. “Already in 2024, we see massive progress: Money lost to fraud in the country declined by 48% in the first quarter of this year compared to Q1 of 2023. It’s difficult to reach any conclusion other than that BioCatch has left Australian digital-banking customers far safer from fraud than they were before.”
Other key findings:
No desktop or laptop needed: BioCatch found as much as 70% of all reported frauds in APAC originated from mobile apps in 2023, an increase of 17% from the year before.Scams are everywhere: Across the region, the number of reported voice scams increased by 108% in 2023.Australia bucking all trends: In addition to seeing fraud losses actually decline, the nation also saw fewer fraud cases involving malware or Remote Administration Tools (RATs) in 2023 than it did in 2022.Click here to access BioCatch’s complete 2024 Digital Banking Fraud Trends in APAC report.
About BioCatch:BioCatch stands at the forefront of digital fraud detection, pioneering behavioral biometric intelligence grounded in advanced cognitive science and machine learning. BioCatch analyzes thousands of user interactions to support a digital banking environment where identity, trust, and ease coexist. Today, more than 30 of the world’s largest 100 banks and 196 total financial institutions rely on BioCatch Connect™ to combat fraud, facilitate digital transformation, and grow customer relationships. BioCatch’s Client Innovation Board – an industry-led initiative featuring American Express, Barclays, Citi Ventures, HSBC, and National Australia Bank – collaborates to pioneer creative and innovative ways to leverage customer relationships for fraud prevention. With more than a decade of data analysis, 92 registered patents, and unmatched expertise, BioCatch continues to lead innovation to address future challenges. For more information, please visit www.biocatch.com.
Media contact:Jay [email protected]
Logo – https://mma.prnewswire.com/media/1843699/biocatch_logo_rgb_2x_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/more-than-150-000-money-laundering-accounts-detected-in-apac-302181474.html

Artificial Intelligence

Puyi Fund, Managed by Highest Performances Holdings Inc., Surpasses RMB 24.0 Billion in Assets under Advice, Showing Promising Start to Strategic Transformation

Published

9 hours ago

June 25, 2024

CISION (PR Newswire)

GUANGZHOU, China, June 25, 2024 /PRNewswire/ — Highest Performances Holdings Inc. (“HPH” or the Group, NASDAQ: HPH), announces that its Puyi Fund’s assets under advice for its asset allocation services reached RMB 24.7 billion as of June 21, 2024, reflecting a remarkable year-on-year growth of 188%. This substantial increase in scale showcases significant growth for the fund.

This accomplishment is primarily attributed to the Puyi Fund’s service philosophy, “long-term commitment to clients and clients’ long-term benefits,” introduced in 2023, as well as the ongoing efforts of the Company in adjusting its product strategy and embracing digital transformation. On one hand, the Company implemented a comprehensive family wealth management account system, redirecting its flagship products towards fixed-income funds and fund portfolios to enhance clients’ perception of wealth acquisition. On the other hand, the Company has elevated its overall service standard through digital transformation, greatly improving the client’s investment experience.
Transforming Product Strategy to Maximize Client Returns
In relation to product strategy transformation, Puyi Fund offers investors a comprehensive solution for managing their family wealth through a scientific approach. This solution guides investors in allocating their investment assets across three types of accounts: Flexible Withdrawal Accounts, Stable Appreciation Accounts, and High-Yield Pursuit Accounts. By considering various market conditions and cycles, investors can make informed decisions on how to distribute their funds among these accounts through a scientific approach for achieving risk mitigation, consistent asset growth, and long-term sustainable investment returns.
Taking into account the prevailing market conditions in China, Puyi Fund advises investors to allocate 25% to 90% of their funds to Stable Appreciation Accounts, depending on their risk tolerance. These accounts primarily involve investing in fixed-income funds, providing investors with consistent and reliable expected returns. By employing the stable appreciation strategy, Puyi Fund aims to restore investors’ confidence in the market, leading to increased trust and recognition. Consequently, Puyi Fund has experienced a period of rapid growth and positive development.
An analysis of data from the Chinese mutual fund market highlights the alignment of Puyi Fund’s client-centric product strategy transformation with market demands. According to Wind data, the market value of the Chinese mutual fund market stood at RMB 25.45 trillion at the end of 2021. By the end of May 2024, this amount grew to RMB 29.09 trillion, representing an increase of RMB 3.64 trillion or 14.30%. The value of equity and hybrid funds, however, experienced a decline from RMB 8.54 trillion to RMB 6.34 trillion, marking a decrease of RMB 2.21 trillion. In contrast, bond funds and money market funds collectively witnessed a significant increase of RMB 5.69 trillion. These market trends suggest that Chinese fund investors are shifting their risk preferences towards lower-risk and higher-certainty assets. Puyi Fund’s strategic transformation is well-positioned to take advantage of this evolving trend.
Enhancing Digital Service Innovation with a Focus on Client Service
In its digital transformation efforts, Puyi Fund places a strong emphasis on “client-centricity” and “service excellence”. By harnessing the power of big data, algorithm mining, and the Sensor Intelligent System, Puyi Fund establishes personalized service scenarios tailored to the unique needs of thousands of individuals. Through meticulous operations that cover the full client lifecycle, Puyi Fund offers full-scope online transactions for both public and private fund clients, establishing a distinctive digital competitive advantage. As of June 2024, the year-to-date client retention rate for fund advisory services stands at 75%, significantly enhancing the likelihood of investment profitability and returns for clients. This success enables clients to truly appreciate the value of advisory services and the time invested in their investments.
Furthermore, Puyi Fund has made continuous advancements in its intelligent client service system, leveraging digital platforms to offer investors comprehensive and efficient services. As of June 2024, the intelligent client service has catered to the needs of approximately 250,000 investors, providing 7*24 services, with a problem resolution rate surpassing 90%. Moreover, Puyi Fund complements intelligent client service with human support, resulting in a client satisfaction rate of 99%. This approach guarantees that investors receive timely and effective assistance whenever required.
Optimizing Trust-Based Communication Channels with Clients
Puyi Fund’s capability to swiftly establish client trust is attributable to its distinctive offline service channels. Unlike other third-party fund sales institutions that heavily rely on online platforms, Puyi Fund provides face-to-face, one-on-one services through offline channels. This approach is especially valuable in navigating complex investment environments, effectively calming investor emotions, enabling them to stay composed and gain a proper understanding of products, ultimately making well-informed investment decisions. Since 2024, Puyi Fund’s research and advisory team has released 28 specialized research reports and organized 19 online client exchanges, along with 35 offline client events, in response to market dynamics and client needs. These initiatives have effectively addressed investors’ concerns and enhanced their confidence.
It is worth mentioning that Puyi Fund’s institutional business has experienced remarkable growth this year, particularly in attracting clients from prominent financial institutions including banks, wealth management subsidiaries, and insurance companies. To cater specifically to institutional investors, Puyi Fund has developed an intelligent over-the-counter fund trading system called “Web-based Institution Master system”. This system provides institutional investors with a wide range of product portfolios, a comprehensive investment research system, and personalized trading experiences. As a result, it comprehensively improves the service quality and efficiency for institutional clients.
As of June 21, Puyi Fund established partnerships with 117 mutual fund companies, including the top 20 fund managers in terms of size, providing access to nearly 11,000 public funds and implementing over 20 customized advisory strategies. In the private fund sector, Puyi Fund has selected over 30 fund managers from the entire market. Of these, 38% manage assets over RMB 10 billion, while 29% manage assets between RMB 5 billion and RMB 10 billion. This selection covers a wide range of mainstream strategy products in the market, catering to the allocation needs of various types of investors.
It is reported that Puyi Fund, an independent third-party fund sales institution holding a fund sales business license issued by the China Securities Regulatory Commission, operates as a subsidiary of Highest Performances Holdings Inc. (NASDAQ: HPH). Embracing the concept of buyer advisor, Puyi Fund is dedicated to delivering comprehensive family financial asset allocation services to individual investors and diversified financial services to institutional investors through its financial technology service platform. With exceptional resource integration capabilities, professional research expertise, and high-quality client service, Puyi Fund strives to cultivate long-term partnerships with clients, catering to their personalized asset allocation needs in various scenarios while assisting a broader range of investors in achieving sustainable long-term returns. As of December 31, 2023, the accumulated assets under Puyi Fund’s allocation advisory services surpassed RMB 75.1 billion, exhibiting a compound annual growth rate of 128.8% from 2015 to 2023.
About Highest Performances Holdings Inc. (NASDAQ: HPH)
HPH was founded in 2010 with the aim of becoming a top provider of smart home and enterprise services. Its mission is to improve the quality of life for families worldwide, focusing on two main driving forces: “technological intelligence” and “capital investments.”HPH has a global strategic perspective and identifies high-quality enterprises with global potential for investment and operations. Its areas of focus include asset allocation, education and study tours, cultural tours, sports events, healthcare and elderly care and family governance.
HPH currently holds controlling interests in two leading financial service providers in China, namely Fanhua Inc., a technology-driven platform, and Fanhua Puyi Fund Distribution Co., Ltd., an independent wealth management service provider.
Highest Performances Holdings Inc., formerly known as Puyi Inc., was renamed on March 13, 2024 to reflect its strategic transformation.

View original content:https://www.prnewswire.co.uk/news-releases/puyi-fund-managed-by-highest-performances-holdings-inc-surpasses-rmb-24-0-billion-in-assets-under-advice-showing-promising-start-to-strategic-transformation-302181854.html